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We investigated the eﬀect of dietary supplementation with n-3 PUFA (ﬁsh oil source) in an experimental model of food allergy.
Mice were sensitized (allergic group) or not (nonallergic group) with OVA and were fed with OVA diet to induce allergy signals.
Micewerefedwithregulardietinwhich7%oflipidcontentwasprovidedbysoybean(5%ofn-3PUFA)orﬁsh(25%ofn-3PUFA)
oil. Allergic group mice had increased serum levels of antiovalbumin IgE and IgG1 and changes in small intestine, characterized by
an increased edema, number of rolling leukocytes in microcirculation, eosinophil inﬁltration, mucus production, and Paneth cell
degranulation, in comparison to non-allergic group. All these inﬂammatory parameters were reduced in mice fed high-n-3-PUFA
diet. Our data together suggest that diet supplementation with n-3 PUFA from ﬁsh oil may consist of a valid adjuvant in food
allergy treatment.
1.Introduction
The normal immune response to dietary proteins is associ-
ated with the induction of oral tolerance, which involves a
modiﬁcation of the antigen in the lumen by gastrointesti-
nal enzymes, the posterior contact with speciﬁc antigen-
presenting cells with distinct activation requirements, and
activation of regulatory T cells. It is well accepted that
a breakdown in oral tolerance mechanism or a failure of
induction of oral tolerance results in food allergy [1, 2].
Food allergies are disorders that aﬀect about 20–30% of
thehumanpopulationindevelopingcountries,makingthem
someofthemostcommonchronicdiseases[3].Itisgenerally
accepted that 6–8% of all children below 3 years of age
present food allergy reactions [4, 5], specially IgE-mediated
hypersensitivities [6]. Milk, eggs, peanuts, chestnuts, and
shrimp are commonly related to food allergy episodes [4, 7].
In these atopic patients, continuous involuntary exposure to
afoodallergenmayinduceamildandpersistentallergiccon-
dition involving skin, gastrointestinal, and respiratory tracts
disorders or trigger a multiple-organ system reaction with
cardiovascular collapse [8]. Therefore, there is considerable
interest in identifying interventions that are able to prevent
or modify this pathological condition.
The main treatment strategy for most food allergies
is based on allergen avoidance, which may present po-
tential adverse nutritional deﬁciencies related to inade-
quate growth, neurological development, and cardiovascular2 Clinical and Developmental Immunology
health [9, 10]. Therapeutic strategies under study include
oral immunotherapy [11], vaccines [12], Chinese herbal
medicines [13], and dietary supplementation strategies with
antioxidants[14].Anotheravailabletherapeuticoptionisthe
use of essential fatty acids for the prevention and treatment
of symptoms of allergies, once the increased prevalence
of allergies has been associated with modern dietary style
(increased consumption of n-6 polyunsaturated fatty acids
(n-6 PUFA) and decreased n-3 polyunsaturated fatty acids
intake (n-3 PUFA)) [15, 16]. However, there is no clear
evidence regarding modulation of immunological proﬁle
with use of n-3 PUFA during allergy.
Based on this, in the present study we evaluated the
eﬀect of chronic intake of n-3 PUFA in a murine model of
food allergy. In order to simulate this persistent food allergy
situation, we used an experimental model of food allergy
in which ovalbumin- (OVA-) sensitized BALB/c mice are
given the antigen orally [17]. This model mimics several
pathological changes that occur in patients with food allergy
including increased anti-OVA IgE and IgG1 production,
intestinal edema, and eosinophil inﬁltration in the small
intestine [18].
2.MaterialsandMethods
2.1. Animals. Female BALB/c mice at four weeks of age were
obtained from our animal facility (ICB/UFMG). All mice
have received water and food ad libitum.T h ep r o c e d u r e s
were in accordance with the Ethical Principles in Animal
Experimentation, adopted by the Ethics Committee in Ani-
mal Experimentation of our institution (CETEA/UFMG).
2.2. Diet. Two diﬀerent diets were prepared in accordance
with AIN-93 components [19], varying in fatty acid com-
position. Mice were fed with regular diet in which 7% of
lipid content was provided by soybean (Control group: 5%
of n-3 PUFA) or ﬁsh oil (n-3 PUFA group: 25% of n-3
PUFA). The diet consumption was started just after weaning
in 4-week-old mice (Figure 1). The fatty acid composition
of the diet is showed in Table 2. Fresh diet was given every
2 days to avoid lipid oxidation. All diets contained 14% of
protein (casein before antigen challenge and ovalbumin for
the antigen challenge; Tables 1 and 2). The fatty acids proﬁle
of ﬁsh oil used in this study was examined by the Chemistry
Department of the Exact Sciences Institute (ICEx/UFMG)
using gas chromatography. The fatty acids proﬁle of the
soybean oil used (Lisa) was obtained by Sanibal and Mancini
Filho, 2004 [20].
2.3. Mice Sensitization and Oral Challenge. After 21 days
(week 3 of experiment) of diet consumption (without
OVA), allergic group (OVA+) received 0.2mL saline (0.9%)
with adjuvant (1mg Al(OH)3)a n d1 0 μgO V A( ﬁ v et i m e s
crystallized hen’s egg albumin; Sigma, St. Louis, Mo, USA).
The nonallergic group (OVA−) received only saline and
adjuvant. After 14 days (week 5), an immunological booster
was given with 10μg OVA to allergic group. At the same
time, nonallergic mice received saline. All injections were
Table 1: Mouse chow ingredients (based on AIN-93G diet).
Ingredient g/kg diet
Protein source
Casein (day 0–21) 200.000
or
Ovalbumin (day 21—end) 200.000
Lipid source
Soybean oil 70.000
or
Fish oil 70.000
Cornstarch 529.500
Sucrose 100.000
Fiber (cellulose) 50.000
Mineral mix (AIN-93G-MX) 35.000
Vitamin mix (AIN-93-VX) 10.000
L-cystine 3.000
Choline bitartrate (41.1% choline) 2.500
Tert-butylhydroquinone 0.014
Table 2: Fatty acid composition of mouse diets.
Fatty acid Fish oil (%) Soy oil (Lisa) (%)
Sum of SFA 30.8 15.24
Sum of MUFA 29 22.69
C18:2 n-6c (LA) 1.3 55.83
C18:3n6 (GLA) 0.2
C20:4 n-6c (AA) 0.0
Sum of n-6PUFA 1.5 55.83
C18:3n3 (ALA) 0.6 4.79
C20:3n3 1.3
C20:5 n-3 (EPA) 15.9 0.0
C22:6 n-3 (DHA) 7.9 0.0
Sum of n-3 PUFA 25.7 4.79
SD 13 0.07
Total 100 100
SFA: saturated acid; MUFA: monounsaturated acid; LA: linoleic acid;
GLA: γ-linolenic acid; AA: arachidonic acid; ALA: α-linolenic acid; DHA:
docosahexaenoic acid; EPA: eicosapentaenoic acid; SD.
performed subcutaneously. After 7 days of booster (week 6),
the two diﬀerent diets remained with the same composition
regarding lipids levels; however, for all groups casein was
replaced by ovalbumin (lyophilized egg white-Salto’s, Belo
Horizonte, MG, Brazil) to induce allergic manifestations in
sensitized mice during 7 days (Figure 1).
2.4. Serum Antibody Evaluation. After 7 days of continuum
challenge with OVA diet (week 7), all mice were anesthetized
with an i.p. injection of a mixture of 10mg/kg xylazine and
200mg/kg ketamine hydrochloride. Serum was collected for
anti-OVA IgG1 and IgE analyses. ELISA for IgG1 was carried
out using plates coated with OVA and 100μL of 1:8000
diluted mouse sera, with goat anti-mouse IgG1 (SouthernClinical and Developmental Immunology 3
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Figure 1: Experimental protocol. BALB/c mice were separated in 4 groups: control/nonallergic, control/allergic, n-3 PUFA/nonallergic, and
n-3PUFA/allergic.Accordingtothediet,micereceived5%n-3PUFA(controlgroup)or25%n-3PUFA(n-3PUFAgroup)assourceoflipids
in their diet since the beginning of the experiment (after weaning) until the end (7th week). According to the immunological procedures,
mice were sensitized and received a booster (allergic group) or not (nonallergic group) with ovalbumin. Seven days after the booster, all mice
received OVA diet (the diet remained with the same proﬁle of lipids but the source of the protein was changed from casein to ovalbumin).
After 7 days, the mice were sacriﬁced and the serum and tissues collected for analyses.
Biotechnology Associates, Birmingham, Ala, USA) and rab-
bit anti-goat labeled with peroxidase (Southern Biotechnol-
ogy Associates, Birmingham, Ala, USA). The plates were
developed with o-phenylenediamine and H2O2 and were
read at 492nm on an automated ELISA reader (EL800, Bio-
Tek Instruments, Inc., Winooski, Vt, USA). Anti-OVA IgE
was measured by capture-ELISA using plates coated with rat
anti-mouse IgE, 50μL of serum, and biotinylated OVA, as
previously described [21]. The results for both antibodies
are reported in arbitrary units (1000A.U) according to the
standard curve obtained with serial dilutions of pooled
serum from OVA-hyperimmunized BALB/c mice.
2.5. Histological Analysis. After 14 days of oral challenge, the
mice were sacriﬁced by cervical dislocation. The proximal
jejunum was taken for histological analysis. It was ﬁxed in
10% formalin in PBS, embedded in paraﬃn and cut into
5μm thick sections. The sections were stained with periodic
acid Schiﬀ (PAS) for mucus analysis or with hematoxylin-
eosin to evaluate eosinophil inﬁltration. Ten ﬁelds from
hematoxylin-eosin-stained sections were randomly chosen
at 40x (53.333μm2/ﬁeld) in order to count the number
of eosinophils, and the data are reported as number of
eosinophils/ﬁeld. For mucus analysis, three sections of the
jejunum stained with periodic acid Schiﬀ were submitted
to morphometric analysis using an image analysis program
running on an IBM computer. Images were obtained at 40x
(53.333μm2/ﬁeld) with a JVC TK-1270/RGB microcamera
and analyzed with the KS300 software built in a Kontron
Eletronick/Carl Zeiss image analyzer. For the determination
of goblet cell volume, all pixels with green hues were selected
forthecreationofabinaryimageandsubsequentcalculation
of the total area, and data were reported as a percentage of
m u c u sa r e a / t o t a la r e a .
2.6. Intravital Microscopy of Intestine Microcirculation. To
study leukocyte recruitment in vivo, animals were anes-
thetized and the abdomen wasopened via a midline incision.
The mice were maintained in constant temperature (34◦C).
A segment of small intestine was chosen and placed onto a
stage, and the microcirculation was imaged using intravital
microscopy by ﬂuorescence microscopy (OLYMPUS BX41).
Rhodamine 6G was used for visualization of rolling and
adhered cells in intestinal microcirculation. Rolling was
measured by counting the number of cells that passed for
a given point during 3 minutes (cells/min) and cells that
remained stopped for 30 seconds in the same point were
counted as an adherent cell.
2.7. Statistical Analysis. The results were expressed as the
mean ± SEM, as indicated in the ﬁgure legends. Signiﬁcance
was determined by the ANOVA-Tukey and Student t-tests,
with P<0.05 deﬁning signiﬁcance over the control group.
3. Results
3.1. Evaluation of Serum Anti-OVA IgG1 and IgE Antibodies.
The experimental allergy protocol induced a signiﬁcant
increase in serum levels of speciﬁc anti-OVA IgE and IgG1.
Interestingly, n-3-PUFA-supplemented mice had signiﬁcant
l o w e rl e v e l so fs p e c i ﬁ ca n t i - O V AI g Ec o m p a r e dt oc o n t r o l
group (Figure 2).
3.2. Intestinal Histology Analyses. The ingestion of OVA diet
induced submucosal edema and increased degranulation of
Paneth cells and inﬂammatory cell inﬁltration in mucosa.
There was 10-fold increase in the number of eosinophils in
control allergic group compared to nonallergic mice. Inter-
estingly, edema and eosinophil inﬁltration were signiﬁcantly4 Clinical and Developmental Immunology
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Figure 2: Dietary supplementation with n-3 PUFA decreases serum concentrations of anti-OVA IgE and IgG1 in BALB/c-sensitized mice.
BALB/c mice received 5% n-3 PUFA (control group) or 25% n-3 PUFA (N-3 PUFA group) as source of lipids in their diet 21 days before
the sensitization. BALB/c mice were sensitized (allergic, OVA+) or not (nonallergic, OVA−) with OVA. Seven days after the booster, all
mice received OVA diet. After 7 days, the mice were sacriﬁced and the serum was collected for measurement of anti-OVA IgE and IgG1 by
ELISA. Data are reported as means ± SEM for 5 animals/group. ∗P<0.05 compared to nonallergic group (OVA−) with the same diet, and
∗∗P<0.05 compared to allergic control group (ANOVA-Tukey).
reduced in mice fed increased n-3 PUFA diet. Also, Paneth
cells from n-3 PUFA-supplemented mice displayed a regular
proﬁle of degranulation, similar to controls (Figure 3).
3.3. Evaluation of Intestinal Mucus by Goblet Cells. Contin-
uous exposure to the antigen induced a signiﬁcant increase
in mucus production by goblet cells in the small intestine
of sensitized wild-type BALB/c mice when compared to
nonsensitized animals. On the other hand, antigen ingestion
induced no increase in mucus secretion in the small intestine
of mice fed with n-3 PUFA diet (Figure 4).
3.4. Intravital Microscopy of Intestine. Leukocyte recruitment
is a hallmark feature of the inﬂammatory response, and it
involvesasequentialseriesofmolecularinteractionsbetween
the leukocyte and endothelial cells [22]. Once we have
detectedareducedeosinophilinﬁltrationinn3-PUFAgroup,
we decided to investigate, by using intravital microscopy, in
which step of leukocyte recruitment this diet was interfering.
Allergic group had an increase in rolling and adhered
leukocyte number in intestinal microvasculature after OVA
diet. However, mice fed n-3 PUFA diet displayed a reduction
in the total number of rolling leukocytes (Figure 5(a))w i t h
no diﬀerences in the number of adherent cells (Figure 5(b)).
4. Discussion
Immunoglobulin-E-dependent food allergy typically aﬀects
the gastrointestinal tract with diﬀerent degrees of eosino-
philic inﬂammation and edema [8]. Food allergy treatment
is mostly based on pharmacological approach (mainly
antihistaminic and corticoids) and food antigen avoidance,
being the last one the only eﬃcacious alternative in several
refractory patients. In this sense, supplements with ability to
decreaseoravoidallergicreactionsagainstfoodcontentsmay
be promising. In the food allergy model used in this study,
when ovalbumin-sensitized mice were given OVA (antigen)
in the diet, several signs of food allergy were observed,
including increased serum antiovalbumin IgG1 and IgE
and marked histological ﬁndings of intestinal inﬂammation
(mucus hypersecretion, eosinophil inﬁltration, Paneth cell
degranulation, and edema) [17]. In the present work, we
have shown that OVA allergic mice had a less severe allergic
response when the polyunsaturated fatty acid omega 3 was
increased in the diet. We provided evidence that reduced
OVA-speciﬁc IgE production by n-3-PUFA-supplemented
diet led to reduced eosinophil inﬁltration into gut mucosa,
with mild intestinal inﬂammatory response in mice. These
data together suggest that food supplementation with n-
3 PUFA may consist of a promising venue to treat food-
associated allergic disorders despite food avoidance.
The known mechanism involved in IgE-dependent food
allergy is attributed to the generation of Th2 cells that
produce IL-4 with further generation of IgE and IgG1
antibodies [8]. These immunoglobulins bound in mast cells
via its high aﬃnity receptor (FcεRI), leading to release of a
large number of proinﬂammatory mediators and proteases
into adjacent tissues [23]. Also, these activated mast cells
produce Th2-type cytokines, including IL3, IL-5, and IL-13,
leading to the accumulation of eosinophils which promote
the expansion of Th2 cells in inﬂamed tissues and release of
proinﬂammatory mediators with upregulation of adhesion
systems, modulation of cellular traﬃcking, activation andClinical and Developmental Immunology 5
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Figure 3: Dietary supplementation with n-3 PUFA decreases histological inﬂammatory parameters in jejunum of BALB/c-sensitized mice.
BALB/c mice received 5% n-3 PUFA (control group) or 25% n-3 PUFA (N-3 PUFA group) as source of lipids in their diet 21 days before
the sensitization. BALB/c mice were sensitized (allergic, OVA+) or not (nonallergic, OVA−) with OVA. Seven days after the booster, all mice
receivedOVAdiet.After7days,themiceweresacriﬁcedandtheintestinewastakenforhistologyanalyses.(a)Nonallergiccontrol;(b)allergic
control; (c) nonallergic n-3 PUFA; (d) allergic n-3 PUFA. Bar = 50μm. In (b), long arrows show eosinophils, short arrows show Paneth cells,
and asterisks show submucosal edema. In (e), data are reported as means ± SEM of number of eosinophils for 5 animals in each group.
∗P<0.05 compared to nonallergic group (OVA−) with the same diet, and ∗∗P<0.05 compared to allergic control group (ANOVA-Tukey).6 Clinical and Developmental Immunology
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Figure 4: Dietary supplementation with n-3 PUFA decreases mucus production in small intestine of BALB/c-sensitized mice. BALB/c mice
received 5% n-3 PUFA (control group) or 25% n-3 PUFA (N-3 PUFA group) as source of lipids in their diet 21 days before the sensitization.
BALB/c mice were sensitized (allergic, OVA+)o rn o t( n o n a l l e r g i c ,O V A −) with OVA. Seven days after the booster, all mice received OVA
diet. After 7 days, the mice were sacriﬁced and the intestine was taken for histology analyses. (a) Nonallergic control; (b) allergic control;
(c) nonallergic n-3 PUFA; (d) allergic n-3 PUFA. Bar = 50μm. In (e), data are reported as means ± SEM of mucus production for 5 mice
in each group. ∗P<0.05 compared to nonallergic group (OVA−) with the same diet, and ∗∗P<0.05 compared to allergic control group
(ANOVA-Tukey).Clinical and Developmental Immunology 7
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Figure 5: Dietary supplementation with n-3 PUFA decreases leukocyte rolling in small intestine of BALB/c-sensitized mice. BALB/c mice
received 5% n-3 PUFA (control group) or 25% n-3 PUFA (n-3 PUFA group) as source of lipids in their diet 21 days before the sensitization.
BALB/c mice were sensitized (allergic, OVA+) or not (nonallergic, OVA−) with OVA. Seven days after the booster, all mice received OVA diet.
After seven days of ingestion of the ovalbumin- (OVA-) containing diet, the leukocyte rolling (a) and adhesion (b) to the microvasculature of
intestine were assayed by intravital microscopy. Data are reported as means ± SEM for 3 mice in each group. ∗P<0.05 compared to control
group (ANOVA-Tukey).
regulationofvascularpermeabilityandmucussecretion,and
tissue damage [24]. The mucosal immune system accounts
for a number of mechanisms to avoid an uncontrolled
immune response against food antigens, including the
presence of regulatory T cells in the lymphoid tissue of the
gut [25] and mucus (a physical barrier against antigens)
[26]. Consistent with this, a reactive increase of mucus
production is expected during food allergy model, which is
reducedin the absenceofIL-4and IgE[27].Additionally, gut
mucosacellsplayakeyroleinthedigestivetracthomeostasis.
Paneth cells are secretory cells in the epithelium of the small
intestine, which reside in small clusters at the base of crypts
ofLieberk¨ uhn,andtheyarethemainsourceorantimicrobial
peptides in gut [28]. These peptides are described to act
protecting gut mucosa against enteric bacterial pathogens,
participating as a key homeostatic role in establishing and
maintaining the intestinal microbiota [29]. In our study,
histological evaluation showed that during food allergy a
degranulation proﬁle is observed in Paneth cells. Although
thereisnoknowndirectcorrelationbetweenPanethcellsand
food allergy, we suggest that these cells may be involved in
allergy-induced gut mucosa inﬂammation.
Thepolyunsaturatedacids(includingn-3andn-6PUFA)
are precursors of several eicosanoids, such as prostaglandins
(PG), leukotrienes, thromboxanes, and hydroxyeicosate-
traenoic acids. Consumption of n-6 PUFA leads to the
formation of speciﬁc eicosanoids with a proinﬂammatory
proﬁle, which has an essential role in allergic inﬂam-
mation. Thereby, linoleic acid (LA; C18:2 n-6), one of
the major dietary n-6 PUFA, is converted to arachidonic
acid (AA; C20:4 n-6) and is incorporated into membrane
phospholipids [30]. During metabolism, AA is released by
phospholipases and metabolized to PGE2, driving a Th2
subset response. In this sense, imbalanced dietary intake
of n-6 PUFA may increase the predisposition to atopic
disorders with IL-4 and consequent IgE production. In
sharp contrast, an increased n-3 PUFA ingestion will lead
to a metabolic competition with n-6 PUFA metabolism,
culminating in decreased synthesis of PGE2, decreased IL-4
and IgE, as seen in our model [27]. Additionally, n-3 PUFA
supplementation in allergic subsets may be beneﬁcial, since a
lessinﬂammatoryenvironment maybe achievedduring fatty
acid metabolism [31].
In fact, n-3 PUFA supplementation leads to a less
severe inﬂammation in gut mucosa from allergic mice
and decreased production of IgE. This statement may be
strengthened by three major ﬁndings. First, lower levels
of IgE were observed in supplemented mice. Mast cells,
which are extremely activated by IgE, can release several
mediators upon IgE activation, IL-5 and eotaxin being
potent chemoattractants to eosinophils. This may explain
the marked reduction in eosinophils observed in n-3-
PUFA-supplemented mice. In fact, a previous report has
shown that both DHA and EPA are able to decrease the
chemotactic and chemokinetic responses of eosinophils in
a dose-dependent fashion [31]. Second, we observed less
mucus production and Paneth cells degranulation in n-
3-PUFA-supplemented mice, which is a clear histological
indication of a mild gut inﬂammatory response [27]. And
ﬁnally, intravital microscopy of intestinal microvasculature
revealed that food enriched with n-3 PUFA by ﬁsh oil led
to a reduction in the total number of rolling leukocytes, as8 Clinical and Developmental Immunology
an indication of reduced endothelial-leukocyte interaction.
Several reports have shown that consumption of n-3 PUFA
in ﬁsh oil may reduce the inﬂammatory response in several
chronic inﬂammatory diseases characterized by leukocyte
accumulationsuchasatherosclerosis,asthma,systemiclupus
erythematosus, inﬂammatory bowel disease, and rheuma-
toid arthritis [32–35]. In a previous report it was shown that
oxidized EPA is a potent inhibitor of leukocyte interaction
with the endothelium. The proposed mechanism responsible
for this eﬀect seems to be the activation of nuclear receptor
peroxisome proliferator-activated receptor α (PPARα)a n d
subsequent downregulation of leukocyte adhesion receptor
expression [36].
Our results are consistent with previous works such as
that performed by Watanabe et al. which showed that the
IgE antibody response against egg albumin was signiﬁcantly
lower in the mice fed with saﬄower seed oil [37]. Also,
Yamashiro et al. have shown that the mucosal damage
inducedbyintestinalhypersensitivityreactionstoovalbumin
is regulated by omega-3-fatty-acid enriched diet [38]. On
the other hand, depending on the model or on the feeding
design, the results can be controversial. For example, Johans-
son et al. have shown that, during the airway hypersensitivity
(Th2), mice fed with ﬁsh oil produced high levels of OVA-
speciﬁc IgE and had slightly high eosinophil inﬁltration into
the lungs. Contrastingly, chronic n-3 PUFA consumption
(as shown in our study) or lipid-based allergy prevention
performed since in the uterus, via maternal diet [39, 40],
provide evidence of beneﬁc immunological modulation and
less inﬂammatory tissue damage. Further basic investigation
may provide guidelines for new trials, since meta-analysis
studies have not conﬁrmed the beneﬁcial role of n-3 or
n-6 PUFA supplementation as a strategy for the primary
prevention of food allergy [41].
In conclusion, we have shown that diet supplementation
with n-3 PUFA from ﬁsh oil led to a reduction of gut
inﬂammatory response against food antigen, which suggests
that n-3 PUFA may modulate the allergic immune response.
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